ArticleJournal of racial and ethnic health disparities2026
Cancer-Specific and Other-Cause Mortality of Asian Pacific Islanders vs. Caucasians Across Eleven Primary Cancers.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSeveral studies reported more favorable cancer-specific mortality (CSM) in Asian Pacific Islanders (APIs) vs. Caucasians. We tested these findings across 11 primary cancers of all stages: cutaneous melanoma, bladder, breast, colorectal, gastric, kidney, liver, lung, nasopharyngeal, prostate, and uterine cancer. MATERIALS AND
methodsWithin the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), we identified APIs and Caucasians with one of the 11 primaries. Multivariable competing risks regression (CRR) models tested the effect of API race/ethnicity on cancer-specific mortality (CSM) and other-cause mortality (OCM).
resultsOverall, 339,576 APIs (8.5%) vs. 3,643,873 (91.5%) Caucasians were identified. The API to Caucasian ratio varied by cancer type, ratio ranged from 1:1.2 for nasopharyngeal cancer (4,007 APIs vs. 4,723 Caucasians) to 1:80.7 for cutaneous melanoma (4,924 vs. 397,549). In general, APIs were younger (median age 64 vs. 67 years) and harbored less frequently localized stage (in ten of 11 primaries), more frequently regional (in nine of 11 primaries) or metastatic (in seven of 11 primaries) stage. In multivariable CRR models, API race/ethnicity predicted lower CSM in eight of 11 primaries (hazard ratios [HRs] ranged 0.80-0.95), except for cutaneous melanoma, kidney, and uterine cancer. Additionally, API race/ethnicity independently predicted lower OCM in ten of 11 primaries (HRs ranged 0.80-0.95), except for cutaneous melanoma. Exploratory analyses separating Asian Americans and Pacific Islanders demonstrated that the observed survival advantage was largely driven by Asian Americans, whereas Pacific Islanders showed distinct demographic, stage distribution, and mortality patterns.
conclusionBy jointly evaluating cancer-specific mortality (CSM) and explicitly reporting other-cause mortality (OCM) across multiple primary cancers using a uniform competing risks framework, this study provides novel and comprehensive evidence that API race/ethnicity, largely driven by Asian Americans, is associated with more favorable survival outcomes in most malignancies, with some exceptions.
Indexed as
Identifiers
41870848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.